Jun 09, 2021 / 12:00PM GMT
Paul Choi - Goldman Sachs Group, Inc., Research Division - Equity Analyst
Okay. Good morning, everyone. I'm Paul Choi, I cover SMID Cap biotechnology here at Goldman Sachs, and it's my pleasure to welcome you to day 2 of the Global Healthcare Conference. Our first session today is with HUTCHMED and joining us from HUTCHMED is CEO, Christian Hogg. What we'll do is follow the format of prior sessions, and I'll kick it off with some introductory remarks here and turn it over to Christian, who will give his overview, and then we'll go into Q&A. If clients along the way have any questions, please feel free to submit them via the webcast portal. Alternatively, you can e-mail them to me directly, and time permitting, I will read them out loud.
But otherwise, I'll turn it over to Christian.
Christian Lawrence Hogg - HUTCHMED(China)Limited-Former CEO&Executive Director
Thanks, Paul. I'll keep the overview brief, so we can get into the Q&A. So HUTCHMED is a company that, as many of
HUTCHMED (China) Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Mar 04, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers